Literature DB >> 33670650

Molecular Targeting of Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor Receptor (VEGFR).

Nichole E M Kaufman1, Simran Dhingra1, Seetharama D Jois2, Maria da Graça H Vicente1.   

Abstract

Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) are two extensively studied membrane-bound receptor tyrosine kinase proteins that are frequently overexpressed in many cancers. As a result, these receptor families constitute attractive targets for imaging and therapeutic applications in the detection and treatment of cancer. This review explores the dynamic structure and structure-function relationships of these two growth factor receptors and their significance as it relates to theranostics of cancer, followed by some of the common inhibition modalities frequently employed to target EGFR and VEGFR, such as tyrosine kinase inhibitors (TKIs), antibodies, nanobodies, and peptides. A summary of the recent advances in molecular imaging techniques, including positron emission tomography (PET), single-photon emission computerized tomography (SPECT), computed tomography (CT), magnetic resonance imaging (MRI), and optical imaging (OI), and in particular, near-IR fluorescence imaging using tetrapyrrolic-based fluorophores, concludes this review.

Entities:  

Keywords:  EGFR; TKI; VEGFR; cancer; imaging; overexpression; peptide; protein; tyrosine kinase

Mesh:

Substances:

Year:  2021        PMID: 33670650      PMCID: PMC7922143          DOI: 10.3390/molecules26041076

Source DB:  PubMed          Journal:  Molecules        ISSN: 1420-3049            Impact factor:   4.411


  174 in total

1.  Immunotargeted nanoshells for integrated cancer imaging and therapy.

Authors:  Christopher Loo; Amanda Lowery; Naomi Halas; Jennifer West; Rebekah Drezek
Journal:  Nano Lett       Date:  2005-04       Impact factor: 11.189

2.  Monoclonal antibody-conjugated superparamagnetic iron oxide nanoparticles for imaging of epidermal growth factor receptor-targeted cells and gliomas.

Authors:  Ketao Mu; Shun Zhang; Tao Ai; Jingjing Jiang; Yihao Yao; Lingyu Jiang; Qing Zhou; Hongbing Xiang; Yanhong Zhu; Xiangliang Yang; Wenzhen Zhu
Journal:  Mol Imaging       Date:  2015       Impact factor: 4.488

3.  Design, synthesis and characterization of peptidomimetic conjugate of BODIPY targeting HER2 protein extracellular domain.

Authors:  Sashikanth Banappagari; Alecia McCall; Krystal Fontenot; M Graca H Vicente; Amit Gujar; Seetharama Satyanarayanajois
Journal:  Eur J Med Chem       Date:  2013-04-28       Impact factor: 6.514

4.  Peptide ligands for targeting the extracellular domain of EGFR: Comparison between linear and cyclic peptides.

Authors:  Tyrslai M Williams; Rushikesh Sable; Sitanshu Singh; Maria Graca H Vicente; Seetharama D Jois
Journal:  Chem Biol Drug Des       Date:  2017-11-16       Impact factor: 2.817

5.  Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies.

Authors:  Yu Zhou; Anne-Laure Goenaga; Brian D Harms; Hao Zou; Jianlong Lou; Fraser Conrad; Gregory P Adams; Birgit Schoeberl; Ulrik B Nielsen; James D Marks
Journal:  Mol Cancer Ther       Date:  2012-05-07       Impact factor: 6.261

Review 6.  Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars.

Authors:  Lee S Rosen; Ira A Jacobs; Ronald L Burkes
Journal:  Target Oncol       Date:  2017-10       Impact factor: 4.493

7.  The use of radiocobalt as a label improves imaging of EGFR using DOTA-conjugated Affibody molecule.

Authors:  Javad Garousi; Ken G Andersson; Johan H Dam; Birgitte B Olsen; Bogdan Mitran; Anna Orlova; Jos Buijs; Stefan Ståhl; John Löfblom; Helge Thisgaard; Vladimir Tolmachev
Journal:  Sci Rep       Date:  2017-07-20       Impact factor: 4.379

8.  Molecular imaging of hepatocellular carcinoma xenografts with epidermal growth factor receptor targeted affibody probes.

Authors:  Ping Zhao; Xiaoyang Yang; Shibo Qi; Hongguang Liu; Han Jiang; Susan Hoppmann; Qizhen Cao; Mei-Sze Chua; Samuel K So; Zhen Cheng
Journal:  Biomed Res Int       Date:  2013-04-21       Impact factor: 3.411

Review 9.  Properties, production, and applications of camelid single-domain antibody fragments.

Authors:  M M Harmsen; H J De Haard
Journal:  Appl Microbiol Biotechnol       Date:  2007-08-18       Impact factor: 4.813

10.  The architecture of EGFR's basal complexes reveals autoinhibition mechanisms in dimers and oligomers.

Authors:  Laura C Zanetti-Domingues; Dimitrios Korovesis; Sarah R Needham; Christopher J Tynan; Shiori Sagawa; Selene K Roberts; Antonija Kuzmanic; Elena Ortiz-Zapater; Purvi Jain; Rob C Roovers; Alireza Lajevardipour; Paul M P van Bergen En Henegouwen; George Santis; Andrew H A Clayton; David T Clarke; Francesco L Gervasio; Yibing Shan; David E Shaw; Daniel J Rolfe; Peter J Parker; Marisa L Martin-Fernandez
Journal:  Nat Commun       Date:  2018-10-18       Impact factor: 14.919

View more
  7 in total

1.  Guhong Injection Protects Against Apoptosis in Cerebral Ischemia by Maintaining Cerebral Microvasculature and Mitochondrial Integrity Through the PI3K/AKT Pathway.

Authors:  Huifen Zhou; Yu He; Jiaqi Zhu; Xiaojie Lin; Juan Chen; Chongyu Shao; Haitong Wan; Jiehong Yang
Journal:  Front Pharmacol       Date:  2021-05-13       Impact factor: 5.810

2.  Gemcitabine cationic polymeric nanoparticles against ovarian cancer: formulation, characterization, and targeted drug delivery.

Authors:  Sankha Bhattacharya; Md Meraj Anjum; Krishna Kumar Patel
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.419

3.  Vorolanib, a novel tyrosine receptor kinase receptor inhibitor with potent preclinical anti-angiogenic and anti-tumor activity.

Authors:  Chris Liang; Xiaobin Yuan; Zhilin Shen; Yang Wang; Lieming Ding
Journal:  Mol Ther Oncolytics       Date:  2022-01-10       Impact factor: 7.200

4.  Bee venom-loaded EGFR-targeting peptide-coupled chitosan nanoparticles for effective therapy of hepatocellular carcinoma by inhibiting EGFR-mediated MEK/ERK pathway.

Authors:  Shaymaa Abdulmalek; Nouf Mostafa; Marwa Gomaa; Mohamed El-Kersh; Ayman I Elkady; Mahmoud Balbaa
Journal:  PLoS One       Date:  2022-08-10       Impact factor: 3.752

Review 5.  Positron emission tomography molecular imaging-based cancer phenotyping.

Authors:  Chentao Jin; Xiaoyun Luo; Xiaoyi Li; Rui Zhou; Yan Zhong; Zhoujiao Xu; Chunyi Cui; Xiaoqing Xing; Hong Zhang; Mei Tian
Journal:  Cancer       Date:  2022-04-13       Impact factor: 6.921

6.  Toward the Development of GE11-Based Radioligands for Imaging of Epidermal Growth Factor Receptor-Positive Tumors.

Authors:  Benedikt Judmann; Diana Braun; Ralf Schirrmacher; Björn Wängler; Gert Fricker; Carmen Wängler
Journal:  ACS Omega       Date:  2022-07-28

Review 7.  Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma.

Authors:  Julie Bolcaen; Shankari Nair; Cathryn H S Driver; Tebatso M G Boshomane; Thomas Ebenhan; Charlot Vandevoorde
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.